<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations and translocations of the JAK2 gene, mapped at 9p24, lead to constitutive activation of JAK2 and its downstream targets </plain></SENT>
<SENT sid="2" pm="."><plain>The presence of JAK2 mutations in <z:hpo ids='HP_0002665'>lymphomas</z:hpo> has been addressed in larger cohorts, but there are little systemic data on numerical and structural JAK2 aberrations in lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>To study the molecular epidemiology of these aberrations and the consecutive activation of the JAK2-STAT pathway in <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, we examined 527 cases, covering the most common entities, in a tissue microarray by fluorescent in situ hybridization with breakable JAK2 probes, and immunohistochemistry for phosphorylated JAK2 (pJAK2) and its preferred downstream pSTAT3 and pSTAT5 </plain></SENT>
<SENT sid="4" pm="."><plain>9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (PMBCLs), 25/77 (33%) Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e>), 3/16 (19%) angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AILTs</z:e>) and 1/5 ALK1(+) anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e>); breaks were observed only in three cases </plain></SENT>
<SENT sid="5" pm="."><plain>pJAK2 expression was most prevalent in PMBCL, peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>pSTAT3 predominated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HLs</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AILTs</z:e>, PMBCLs and peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>pSTAT5 expression was detected frequently in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AILTs</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>9p24 gains correlated with increased proportions of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells expressing pJAK2 (P=0.002) and pSTAT3 (P=0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>In follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, concomitant expression of pJAK2 and pSTAT5 was linked to better prognosis, whereas expression of pSTAT3 in nongerminal center-like diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> could identify a patient group with an inferior outcome </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings stress that despite the rarity of activating JAK2 mutations in <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, JAK2 is recurrently targeted by numerical, and rarely by structural, genetic aberrations in distinct <z:hpo ids='HP_0002665'>lymphoma</z:hpo> subtypes and that JAK2-STAT pathway may play a role in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
</text></document>